Arm

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Retrieved on: 
Thursday, March 7, 2024

WORCESTER, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced Phase 1 clinical data were published in Nature Medicine that demonstrated the promising safety and clinical activity of Mustang’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma.

Key Points: 
  • MB-101 was developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Mustang.
  • Central nervous system (CNS) increases in inflammatory cytokines, including IFNγ, CXCL9, and CXCL10, were associated with CAR T-cell administration and bioactivity.
  • Primary endpoints were safety and feasibility, with secondary endpoints measuring therapy-related cytokine dynamics, CAR T-cell persistence and clinical outcomes.
  • Dr. Brown has a financial interest in Mustang and has previously been a paid consultant for the company.

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024

WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • “Werewolf made considerable progress in 2023, setting up 2024 as a year of execution across our pipeline,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf.
  • Financial Results for the Fourth Quarter and Full Year 2023:
    Cash position: As of December 31, 2023, cash and cash equivalents were $134.3 million, compared to $129.3 million as of December 31, 2022.
  • Net loss: Net loss was $12.0 million for the fourth quarter of 2023, compared to $11.9 million for the same period in 2022.
  • Net loss was $37.4 million for the full year 2023, compared to $53.8 million for the full year 2022.

STMicroelectronics powers up the intelligent edge with second-generation STM32 microprocessors, bringing performance boost and industrial resilience

Retrieved on: 
Thursday, March 7, 2024

ST’s new STM32MP2 MPUs will power the next generations of equipment that create the fabric of this evolving digital world.

Key Points: 
  • ST’s new STM32MP2 MPUs will power the next generations of equipment that create the fabric of this evolving digital world.
  • These include industrial controllers and machine-vision systems, scanners, medical wearables, data aggregators, network gateways, smart appliances, and industrial and domestic robots.
  • The devices are fully supported with STM32 development resources that are familiar to engineers working with ST’s STM32 microcontrollers (MCUs) and STM32 microprocessors.
  • * STM32 is a registered and/or unregistered trademark of STMicroelectronics International NV or its affiliates in the EU and/or elsewhere.

ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication

Retrieved on: 
Wednesday, March 6, 2024

“ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Key Points: 
  • “ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.
  • Participants received incentives and support to adhere to their daily oral medication to first achieve viral suppression and if successful, they were randomized to either receive long-acting injectable treatment every four weeks or continue taking daily oral medication.
  • The long-acting injectable treatment was more effective than the daily oral medication at maintaining virologic suppression and avoiding treatment-related discontinuation.
  • Twenty-eight participants receiving the long-acting injectable treatment experienced regimen failure (defined as virologic failure or treatment discontinuation), compared to 47 receiving daily oral medication.

BioElectronics Corporation Announces the Publication of Pilot Study Results

Retrieved on: 
Friday, February 23, 2024

FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device.

Key Points: 
  • FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation ( https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device.
  • "Treating intractable postamputation pain with wearable, non-invasive, non-thermal, pulsed shortwave (radiofrequency) therapy: a randomized, double-masked, sham-controlled, crossover pilot study" is now published at: https://rapm.bmj.com/content/early/2024/02/21/rapm-2023-105154 The study was investigator sponsored and funded by the University of California San Diego Department of Anesthesiology.
  • The study design had patients first wear BioElectronics’ Model 088 device (about ½ wore the sham device and the remaining wore the active device) on the residual part of the limb for 28 days.
  • Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device to address this significant unmet medical need.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 22, 2024

Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.

Key Points: 
  • Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.
  • Enrollment in both trials is ongoing, with topline data expected to be reported in the first half of 2025.
  • Kymera unveiled its first-in-class oral STAT6 degrader, KT-621, at its Immunology R&D Day in January.
  • To access the conference call via phone, please dial +1 (833) 630-2127 or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.

The Eclipse Foundation Showcases Successful Open Source Industry Collaborations for 2023; Looks Ahead to Additional Growth in 2024

Retrieved on: 
Tuesday, February 20, 2024

“While we’re thrilled with the growth of our industry collaborations in 2023, we’re always striving to exceed our own goals,” said Mike Milinkovich, executive director of the Eclipse Foundation.

Key Points: 
  • “While we’re thrilled with the growth of our industry collaborations in 2023, we’re always striving to exceed our own goals,” said Mike Milinkovich, executive director of the Eclipse Foundation.
  • Branding and marketing: The foundation develops and implements strategies to establish and promote distinctive identities for our open source projects and industry collaborations.
  • Specification development: The Eclipse Foundation helps our industry collaborations significantly reduce costs and streamline the effort to develop industry consensus specifications using the Eclipse Foundation Specification Process.
  • Get started collaborating at the Eclipse Foundation by joining an existing community or bringing your industry-changing collaboration to the foundation.

CNH takes minority investment in drone imaging AI company Bem Agro  

Retrieved on: 
Tuesday, February 20, 2024

To further our offering in this field, our investment arm CNH Ventures has taken a minority stake in Bem Agro – a Brazilian startup and existing supplier to CNH.

Key Points: 
  • To further our offering in this field, our investment arm CNH Ventures has taken a minority stake in Bem Agro – a Brazilian startup and existing supplier to CNH.
  • Bem Agro uses AI to convert any type of aerial field image – including those taken from machines, drones and satellites – into Agronomic Mapping Reports.
  • This investment follows over five years of successful commercial partnership with Bem Agro.
  • We are excited to expand our collaboration with Bem Agro and further empower farmers to keep Breaking New Ground.

Edge Impulse Deploys its State-of-the-Art Edge AI Models to Arm Microcontrollers Tools

Retrieved on: 
Thursday, March 7, 2024

Easily integrate state-of-the-art Edge Impulse AI and ML models optimized for edge devices into embedded firmware.

Key Points: 
  • Easily integrate state-of-the-art Edge Impulse AI and ML models optimized for edge devices into embedded firmware.
  • Remove hardware lock-in by leveraging edge AI support for the broad range of over 10,000 Arm-based MCUs that are supported by CMSIS.
  • “ML and AI functionality are becoming more widely adopted for edge use cases, and embedded developers need tools to navigate these complexities,” said Reinhard Keil, senior director of embedded technology at Arm.
  • Integrating Edge Impulse’s edge AI tools within it brings additional capabilities to a vast community of developers enabling them to build sophisticated edge AI firmware faster than ever on Arm.”
    “Serving embedded engineers with new tools that help them get started with AI and ML projects quickly is an important priority to us, and working with Arm to support Keil Studio enables us to impact one of the largest communities in edge development,” said Jan Jongboom, co-founder and CTO at Edge Impulse.

Red Trail Energy Is First Ethanol Plant to Enter Voluntary Carbon Markets

Retrieved on: 
Wednesday, March 6, 2024

Red Trail Energy, LLC (RTE), and Puro.earth today announced issuance of RTE’s carbon dioxide (CO2) removal credits on the Puro Registry, making it the first ethanol production facility to generate CO2 Removal Certificates (CORCs) in the voluntary carbon market (VCM) and the largest durable carbon removal project registered to date.

Key Points: 
  • Red Trail Energy, LLC (RTE), and Puro.earth today announced issuance of RTE’s carbon dioxide (CO2) removal credits on the Puro Registry, making it the first ethanol production facility to generate CO2 Removal Certificates (CORCs) in the voluntary carbon market (VCM) and the largest durable carbon removal project registered to date.
  • View the full release here: https://www.businesswire.com/news/home/20240306717962/en/
    North Dakota-based Red Trail Energy is the first ethanol plant to participate in the voluntary carbon markets.
  • The carbon dioxide removal (CDR) credits are generated through bioenergy with carbon capture and storage (BECCS) from ethanol production in compliance with Puro’s Geologically Stored Carbon Methodology.
  • CO2 Removal Certificate sales in voluntary markets are necessary to support building out CCS projects while reducing carbon removal project financial risks.